CDC Changes Hepatitis B Vaccine Recommendations: Risks to Infants?

A recent decision by an advisory committee to the Centers for Disease Control and Prevention (CDC) has altered recommendations for hepatitis B vaccination in newborns, a change that public health experts say could leave some infants vulnerable to infection. For over three decades, the CDC has recommended universal vaccination of all newborns against hepatitis B before hospital discharge, followed by subsequent doses at one to two months and six to eighteen months.

This long-standing vaccination program has been remarkably successful. Data indicates a 99% reduction in acute hepatitis B infections among children and teenagers between 1990 and 2019. Despite this success, the Advisory Committee on Immunization Practices (ACIP) voted to narrow the recommendations. The updated guidance now stipulates that only infants born to mothers known to have hepatitis B, or whose status is unknown, should receive the vaccine at birth. For all other newborns, parents are advised to discuss the timing of vaccination with their pediatrician.

The changes extend to subsequent doses as well. The new recommendations suggest testing infants for antibodies between doses, with the results informing decisions about additional vaccinations. Experts note that this approach has not been previously tested or studied.

The ACIP has framed these changes as promoting shared decision-making between parents and healthcare providers. However, many experts express concern that this shift will create confusion and potentially lead to decreased vaccination rates.

Understanding Hepatitis B: A Highly Contagious Virus

Hepatitis B is a viral infection that attacks the liver and is transmitted through contact with infected body fluids, including blood, semen, and vaginal secretions. Common modes of transmission include sexual contact and shared needles during drug use. While less common, the virus can also be spread through everyday items like toothbrushes, razors, and nail clippers, as the virus can survive outside the body for up to seven days.

The most common route of transmission to newborns is from mother to child during birth. While pregnant women are routinely screened for hepatitis B, access to prenatal care isn’t universal, meaning some infections may go undetected. Even with screening, the risk remains.

Vaccinating all newborns within 24 hours of birth provides crucial protection during delivery and throughout infancy, a period when the consequences of infection are most severe.

The Risks of Hepatitis B in Infants and Children

Hepatitis B can manifest as an acute infection with mild or no symptoms. Many individuals clear the virus on their own without treatment, developing immunity to future infection. However, for others, the infection becomes chronic, lasting a lifetime and potentially leading to serious liver damage, liver failure, liver cancer, and even death.

Infants and young children are particularly vulnerable.

Babies infected with hepatitis B at birth or within their first year of life have a 90% chance of developing a chronic infection

, according to available data. In comparison, children infected between ages one and five have approximately a 30% chance of developing a chronic infection. Tragically, an estimated 25% of chronically infected babies and young children will eventually die from the disease.

The Safety and Efficacy of the Hepatitis B Vaccine

The hepatitis B vaccine has a well-established safety profile. Over a billion doses have been administered worldwide since 1982, with the most common side effects being mild and temporary, such as headache, fever, or soreness at the injection site.

The vaccine’s effectiveness is also well-documented. As demonstrated by the significant decline in reported acute hepatitis B infections since the vaccine’s introduction in 1982 – a reduction of 88.5% from 9.6 cases per 100,000 population to 1.1 cases per 100,000 population in 2015 – the vaccine demonstrably protects against infection.

The CDC’s recent shift towards individual-based decision-making for hepatitis B vaccination represents a significant change in public health strategy. While proponents emphasize parental autonomy, concerns remain about the potential for decreased vaccination rates and increased risk of infection, particularly among vulnerable infants. As of December 16, 2025, the CDC has adopted this new approach, updating its immunization schedule and clinical guidance to reflect the ACIP’s recommendations. Infants born to mothers who test positive for hepatitis B or whose status is unknown will continue to receive the vaccine within 12 hours of birth, while parents of other newborns will be encouraged to discuss vaccination options with their healthcare providers.